Meeting
2012 Gastrointestinal Cancers Symposium
Retrospective analysis of neoadjuvant chemoradiotherapy for esophageal cancer: The Knight Cancer Institute experience.
Authors
Faisal A Siddiqui
Knight Cancer Institute, Oregon Health and Science University, Portland, OR
Faisal A Siddiqui , James P. Dolan , John G. Hunter , Miriam A. Douthit , Lisa M. Bloker , John M Holland , Charles R. Thomas Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 30, 2012 (suppl 4; abstr 126)
DOI
10.1200/jco.2012.30.4_suppl.126
Abstract #
126
Poster Bd #
C42
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Influence of tumor response and treatment schedule on the distribution of tumor recurrence in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
First Author: Kristien M. Jipping
Poster
2022 ASCO Annual Meeting
Preoperative chemoradiation (CRT) with carboplatin (CBP)/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial.
First Author: Antoine Adenis
Poster
2021 ASCO Annual Meeting
Survival (OS) and progression-free survival (PFS) results after induction chemotherapy (IC) followed by de-escalated chemoradiotherapy (RDCRT) for locally advanced (LA) HPV positive oropharynx cancer (HPVOPC.
First Author: Marshall R. Posner
Poster
2020 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy (TPF regimen) followed with robotic surgery and its impact on outcome in management of esophageal cancers: Indian experience.
First Author: S.P. Somashekhar